Dive into the complex landscape of immune checkpoint inhibitors (ICIs) in lung cancer in our poster presentation.
As the use of immunotherapy in early-stage non-small cell lung cancer (NSCLC) remains a challenge, we offer a spatially-informed approach to identify useful biomarkers. By using spatial biomarker assays, and analysis involving spatial transcriptomics and proteomics, we reveal the cell-to-cell interactions in the tumor microenvironment.
Download our poster to explore our findings and gain insights into the suitability of ICIs for personalized therapy
CONTACT US to learn more about Aliri’s extensive experience with this technology.